Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaxibotulinumtoxinA for moderate to severe glabellar lines (China Phase 3)
CTR20202553Phase 3Completed
- Sponsor
- Revance Therapeutics
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A in glabellar furrowing, sponsored by Revance Therapeutics. Started Dec 2020; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on CTR20202553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202553.